Market Overview

Frequency Therapeutics Strengthens Scientific Advisory Board with Addition of Leading Experts in Neurology, Stem Cell and Regenerative Medicine

Share:

Robin Franklin, Ph.D., Professor of Stem Cell Medicine at the
Wellcome Trust-MRC Cambridge Stem Cell Institute

Sheng Ding, Ph.D., William K. Bowes, Jr. Distinguished Investigator
and Professor at Gladstone Institute

Frequency
Therapeutics
, a clinical stage biotechnology company, today
announced the addition of two new members to its PCA Regenerative
Medicine Scientific Advisory Board, Robin Franklin, Ph.D., Professor of
Stem Cell Medicine at the Wellcome Trust-MRC Cambridge Stem Cell
Institute, Director of the MS Society Cambridge Centre for Myelin Repair
and Fellow of the Academy of Medical Sciences and Sheng Ding, Ph.D.,
William K. Bowes, Jr. Distinguished Investigator and Professor at
Gladstone Institute of Cardiovascular Disease, and Department of
Pharmaceutical Chemistry, University of California San Francisco. These
two individuals bring combined decades of experience in stem cell
biology and regeneration including the use of small molecules to control
and activate cell functions.

"Frequency continues to bring together world-renowned scientists with
extensive expertise in the fields of stem cell biology and regenerative
medicine to build and guide our growing PCA Regeneration pipeline in
areas such as diabetes, muscle conditions and demyelination diseases,"
said Chris Loose, Ph.D., Co-founder and CSO of Frequency. "The additions
of Dr. Franklin and Dr. Ding to our PCA Regenerative Medicine SAB will
provide sound guidance and deep knowledge to our scientific leadership
as we explore new therapeutic opportunities."

"Frequency's PCA approach presents a unique opportunity to address stem
cell regeneration and tissue repair through the use of small molecules,
something I have devoted my career to understanding," said Dr. Ding. "I
am honored to join this prestigious group of individuals on the
Regenerative Medicine Advisory Board and eager to provide my knowledge
and research expertise to this burgeoning company."

PCA Regeneration, also known as Progenitor Cell Activation, utilizes
small molecules locally administered to temporarily stimulate dormant
cells in the body's niche micro-environment to address biological
deficits and restore healthy tissue. This is conducted without the
complexity or risks of generational or systemic issues typically
associated with cell and gene therapies. This novel approach has the
potential to yield a whole new category of disease-modifying
therapeutics for a wide range of conditions and diseases including
hearing loss, demyelination diseases such as multiple sclerosis, muscle
conditions, diabetes and gastrointestinal indications.

"Having spent years studying CNS regeneration with a particular focus on
remyelination, the potential for PCA Regeneration to be applied to this
work has strong precedent," said Dr. Franklin. "I look forward to
working with the Frequency team to provide guidance and insight on the
potential use of PCA Regeneration to treat such a complicated CNS
indication as demyelinating diseases and to further develop the
Company's PCA technology as a potentially safer and simpler approach to
treating disease."

Dr. Franklin and Dr. Ding join a prestigious groups of individuals on
Frequency's PCA Scientific Advisory Board which includes Sean Morrison,
Ph.D., a Howard Hughes Medical Institute Investigator, Siddhartha
Mukherjee, M.D., D.Phil., of Columbia University, Lee Rubin, Ph.D., of
the Harvard Stem Cell Institute, Amy Wagers, Ph.D., of Harvard
University and the Joslin Diabetes Center, Frequency's CSO Chris Loose,
Ph.D., and Frequency's co-scientific founders, Bob Langer, Sc.D., of MIT
and Jeff Karp, Ph.D., of Harvard Medical School and Brigham and Women's
Hospital.

The Frequency Therapeutics PCA Regenerative Medicine Scientific Advisory
Board New Members:

  • Robin Franklin, Ph.D., is Professor of Stem Cell Medicine. He
    obtained his undergraduate degrees in Physiology and Veterinary
    Medicine and his Ph.D. in Neuroscience. He has worked predominantly on
    the biology of myelin regeneration (remyelination) and investigating
    strategies by which this important regenerative process may be
    enhanced therapeutically. He is at the forefront of studying the
    cellular mechanisms of remyelination, providing insights into how
    adult stem cells are recruited to areas of demyelination and the
    extrinsic and intrinsic factors that regulate their differentiation
    into remyelinating oligodendrocytes and other glial cell types. He is
    also Director of the UK MS Society Cambridge Centre for Myelin Repair,
    a consortium of Cambridge-based scientists and clinicians working
    towards stem-cell-based therapies for myelin regeneration. He is a
    Fellow of the Academy of Medical Sciences.
  • Sheng Ding, Ph.D. is William K. Bowes, Jr. Distinguished
    Investigator and Professor at Gladstone Institute of Cardiovascular
    Disease, and Department of Pharmaceutical Chemistry, University of
    California San Francisco. Dr. Ding earned his Ph.D. in chemistry from
    the Scripps Research Institute and his B.S. in chemistry from the
    California Institute of Technology. Dr. Ding has pioneered the
    development and application of innovative chemical approaches to stem
    cell biology and regeneration, with a focus on discovering and
    characterizing novel small molecules that can control various cell
    fate/function, including stem cell maintenance, activation,
    differentiation and reprogramming.

ABOUT PCA REGENERATION
Tissue regeneration with Progenitor
Cell Activation, or PCA
Regeneration
, is a new therapeutic approach to repairing damaged
tissue and restoring health function in a less complex and potentially
safer manner than traditional cell and gene therapy. The approach, based
on discoveries in progenitor cell biology from the labs of Bob Langer,
Sc.D., at MIT and Jeff Karp, Ph.D., at Harvard Medical School and
Brigham and Women's Hospital, utilizes small molecules to awaken dormant
progenitor cells already in the body and has the opportunity to address
numerous degenerative diseases such as hearing loss, demyelinating
diseases, skin disorders and gastrointestinal conditions.

ABOUT FREQUENCY THERAPEUTICS
Frequency Therapeutics develops
small molecule drugs to stimulate cells in the body to reverse
biological deficits and restore healthy tissue. Through the transitory
activation of these cells, Frequency enables disease modification
without the complexity of genetic engineering. Our ground-breaking
therapy uses a proprietary combination of small-molecule drugs that
induce progenitor cells to multiply and create new cells. While
Frequency's lead program targets hearing restoration, our PCA
Regeneration platform has the potential to touch upon a wide breadth of
disease indications. www.frequencytx.com.

View Comments and Join the Discussion!